BioMerieux SA
BIM
Company Profile
Business description
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMérieux is headquartered in Marcy-l'Etoile, France.
Contact
Marcy l’Etoile
Lyon69280
FRAT: +33 478872000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
14,754
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,796.20 | 32.50 | -0.37% |
| CAC 40 | 7,766.71 | 43.24 | 0.56% |
| DAX 40 | 24,206.91 | 133.24 | 0.55% |
| Dow JONES (US) | 44,240.76 | 165.60 | -0.37% |
| FTSE 100 | 8,854.18 | 47.65 | 0.54% |
| HKSE | 23,970.39 | 177.68 | -0.74% |
| NASDAQ | 20,418.46 | 5.95 | 0.03% |
| Nikkei 225 | 39,747.53 | 58.72 | 0.15% |
| NZX 50 Index | 12,791.92 | 67.10 | -0.52% |
| S&P 500 | 6,225.52 | 4.46 | -0.07% |
| S&P/ASX 200 | 8,558.00 | 32.70 | -0.38% |
| SSE Composite Index | 3,507.69 | 10.22 | 0.29% |